[go: up one dir, main page]

MX2020001428A - Composiciones de grapiprant y metodos para usar las mismas. - Google Patents

Composiciones de grapiprant y metodos para usar las mismas.

Info

Publication number
MX2020001428A
MX2020001428A MX2020001428A MX2020001428A MX2020001428A MX 2020001428 A MX2020001428 A MX 2020001428A MX 2020001428 A MX2020001428 A MX 2020001428A MX 2020001428 A MX2020001428 A MX 2020001428A MX 2020001428 A MX2020001428 A MX 2020001428A
Authority
MX
Mexico
Prior art keywords
grapiprant
human animal
compositions
methods
same
Prior art date
Application number
MX2020001428A
Other languages
English (en)
Inventor
Devaraj Gopinath
RAUSCH-DERRA Lesley
NEWBOLD Tamara
Shiraishi Akemi
Original Assignee
Aratana Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54016294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020001428(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aratana Therapeutics Inc filed Critical Aratana Therapeutics Inc
Publication of MX2020001428A publication Critical patent/MX2020001428A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente descripción proporciona un método para el tratamiento del dolor o la inflamación en un animal no humano con necesidad del mismo. El método comprende la administración a un animal no humano de una composición farmacéutica que comprende una cantidad terapéuticamente eficaz de grapiprant. También se proporcionan en la presente composiciones farmacéuticas para el tratamiento del dolor o la inflamación en un animal no humano con necesidad del mismo. Las composiciones farmacéuticas comprenden una cantidad terapéuticamente eficaz de grapiprant y un excipiente, incluyendo saborizantes.
MX2020001428A 2014-03-06 2016-08-24 Composiciones de grapiprant y metodos para usar las mismas. MX2020001428A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461948957P 2014-03-06 2014-03-06
US201462089713P 2014-12-09 2014-12-09

Publications (1)

Publication Number Publication Date
MX2020001428A true MX2020001428A (es) 2020-03-20

Family

ID=54016294

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2016011025A MX376175B (es) 2014-03-06 2015-03-05 Composiciones de grapiprant y metodos para usar las mismas.
MX2020001428A MX2020001428A (es) 2014-03-06 2016-08-24 Composiciones de grapiprant y metodos para usar las mismas.
MX2022014763A MX2022014763A (es) 2014-03-06 2016-08-24 Composiciones de grapiprant y metodos para usar las mismas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016011025A MX376175B (es) 2014-03-06 2015-03-05 Composiciones de grapiprant y metodos para usar las mismas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022014763A MX2022014763A (es) 2014-03-06 2016-08-24 Composiciones de grapiprant y metodos para usar las mismas.

Country Status (15)

Country Link
US (3) US11369621B2 (es)
EP (1) EP3113774B1 (es)
JP (1) JP6419857B2 (es)
KR (1) KR102270323B1 (es)
CN (2) CN105939713A (es)
AU (1) AU2015227059B2 (es)
CA (1) CA2941008C (es)
DK (1) DK3113774T3 (es)
ES (1) ES2907285T3 (es)
MX (3) MX376175B (es)
PL (1) PL3113774T3 (es)
PT (1) PT3113774T (es)
RU (1) RU2679631C2 (es)
TW (2) TWI708606B (es)
WO (1) WO2015134792A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12109218B2 (en) * 2014-12-09 2024-10-08 Aratana Therapeutics, Inc. Compositions of grapiprant and methods for using the same
ES2907285T3 (es) * 2014-03-06 2022-04-22 Elanco Animal Health Incorporated Composiciones de grapiprant y procedimientos de uso de las mismas
WO2020014465A1 (en) * 2018-07-11 2020-01-16 Arrys Therapeutics, Inc. Polymorphic compounds and uses thereof
JP2022500485A (ja) * 2018-09-27 2022-01-04 アリーズ セラピューティクス， インコーポレイテッド グラピプラント単位剤形
WO2021205367A1 (en) * 2020-04-08 2021-10-14 Askat Inc. Use of ep4 receptor antagonists for the treatment of liver cancer, melanoma, lymphoma and leukemia

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2479A1 (fr) * 1997-05-05 2003-02-01 Pfizer Composés inhibiteurs sélectifs de cox-2 anti-inflammatoires et compositions pharmaceutiques les contenant.
ES2225199T3 (es) 1999-08-10 2005-03-16 Glaxo Group Limited Uso de ligandos del receptor ep4 en el tratamiento del dolor neuropatico.
HN2001000224A (es) * 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
WO2003008637A2 (en) 2001-07-17 2003-01-30 Xanthus Life Sciences, Inc. Use of genotyping in the individualization of therapy
JP2005511562A (ja) * 2001-10-31 2005-04-28 メディカル リサーチ カウンシル 月経困難症及び月経過多の治療のためのプロスタグランジンレセプターｅｐ２及び／又はｅｐ４のアンタゴニスト
JP2005533756A (ja) 2002-04-12 2005-11-10 ファイザー株式会社 Ｉｌ−６関連疾病の治療におけるｅｐ４レセプターリガンドの使用
MXPA06012172A (es) * 2004-04-20 2007-01-17 Pfizer Prod Inc Combinaciones que comprenden ligandos alfa-2-delta y antagonistas del receptor ep4.
WO2006095268A1 (en) 2005-03-11 2006-09-14 Pfizer Japan Inc. Crystal forms of an imidazole derivative
ES2392192T3 (es) * 2006-04-24 2012-12-05 Merck Canada Inc. Derivados de indol amida como antagonistas del receptor EP4
US20080242713A1 (en) * 2007-03-28 2008-10-02 Bayer Schering Pharma Aktiengesellschaft Novel 5-cyano-prostacyclin derivatives as agents for the treatment of autoimmune diseases
US9457084B2 (en) 2010-02-22 2016-10-04 Raqualia Pharma Inc. Use of EP4 receptor antagonists in the treatment of IL-23 mediated diseases
EP2555774B1 (de) * 2010-04-08 2015-10-21 Boehringer Ingelheim International GmbH Arnzeimittelkombinationen enthaltend pde4-inhibitoren und ep4-rezeptor-antagonisten
CA2814054A1 (en) 2010-10-12 2012-04-19 Merz Pharma Gmbh & Co. Kgaa Formulation suitable for stabilizing proteins, which is free of mammalian excipients
MX2013010306A (es) 2011-03-08 2013-12-09 Zalicus Pharmaceuticals Ltd Formulaciones de dispersion solida y metodos de uso de las mismas.
CA2836372C (en) 2011-05-18 2020-09-22 Raqualia Pharma Inc. Polymorph form of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2h-pyran-4-carboxylic acid
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
HK1220386A1 (zh) 2013-03-19 2017-05-05 Askat Inc. Ep4受体拮抗剂在软骨疾病的治疗中的用途
US12109218B2 (en) * 2014-12-09 2024-10-08 Aratana Therapeutics, Inc. Compositions of grapiprant and methods for using the same
ES2919346T3 (es) 2014-03-06 2022-07-26 Elanco Animal Health Incorporated Forma cristalina x2 de grapiprant
ES2907285T3 (es) * 2014-03-06 2022-04-22 Elanco Animal Health Incorporated Composiciones de grapiprant y procedimientos de uso de las mismas

Also Published As

Publication number Publication date
NZ724007A (en) 2021-02-26
EP3113774A4 (en) 2017-10-25
RU2019102384A3 (es) 2022-03-31
CN105939713A (zh) 2016-09-14
NZ761827A (en) 2021-03-26
TWI664969B (zh) 2019-07-11
RU2019102384A (ru) 2019-03-04
MX2022014763A (es) 2023-01-11
US11369621B2 (en) 2022-06-28
US12478633B2 (en) 2025-11-25
DK3113774T3 (da) 2022-03-07
US20160317559A1 (en) 2016-11-03
TWI708606B (zh) 2020-11-01
RU2679631C2 (ru) 2019-02-12
CA2941008C (en) 2022-07-26
US20250025481A1 (en) 2025-01-23
MX2016011025A (es) 2016-11-29
MX376175B (es) 2025-03-07
KR20160129887A (ko) 2016-11-09
RU2016137926A (ru) 2018-04-09
JP2017507190A (ja) 2017-03-16
KR102270323B1 (ko) 2021-06-29
TW201815393A (zh) 2018-05-01
TW201603812A (zh) 2016-02-01
EP3113774A1 (en) 2017-01-11
AU2015227059A1 (en) 2016-09-22
ES2907285T3 (es) 2022-04-22
JP6419857B2 (ja) 2018-11-07
CA2941008A1 (en) 2015-09-11
AU2015227059B2 (en) 2018-11-15
US20150250773A1 (en) 2015-09-10
PT3113774T (pt) 2022-02-28
CN112370450A (zh) 2021-02-19
EP3113774B1 (en) 2022-01-26
PL3113774T3 (pl) 2022-06-13
WO2015134792A1 (en) 2015-09-11

Similar Documents

Publication Publication Date Title
ZA202308496B (en) Pharmaceutical compositions of therapeutically active compounds
PH12019501414A1 (en) Amino acid compositions and methods for the treatment of liver diseases
PH12016501788A1 (en) Pharmaceutical compositions of therapeutically active compounds
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
MY188139A (en) Sodium channel modulators for the treatment of pain
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MX394452B (es) Inhibicion de la actividad de olig2.
EA201591507A1 (ru) Лечение рассеянного склероза лахинимодом
MX2022014763A (es) Composiciones de grapiprant y metodos para usar las mismas.
MX2018005628A (es) Tratamientos de grasa acumulada con acido desoxicolico y sales del mismo.
PH12016500910A1 (en) Long-acting ketoprofen compositions
EP4302825A3 (en) Pharmaceutical compositions for treatment of inappetence
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
MX394015B (es) Inhibición de la actividad de la olig2.
MX2014014814A (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
NZ724799A (en) Compositions and methods for the treatment or prevention of neurodegenerative disorders
IN2013MU03428A (es)
AR130700A2 (es) Composiciones de grapiprant y métodos para su utilización
NZ725354A (en) Transdermal formulations of pergolide and uses thereof
PH12020500472A1 (en) Autotaxin inhibitor compounds
MX2016010919A (es) 4-bencilsulfonil-2-butenonitrilo.
ZA201606135B (en) Pharmaceutical compositions of therapeutically active compounds
AR099681A1 (es) Composiciones de grapiprant y métodos para su utilización